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Abstract
Haematopoiesis requires the constant production of large 
numbers of peripheral blood cells. This process is under tight 
control of transcription factor networks as well as cytokines, 
growth factors and hormones. We will review the importance 
of transcription factors in programming the haematopoietic 
lineage commitment and the role of the microenvironment 
and the corresponding cellular sensitivity to ensure production 
of mature functional cells in response to the physiological 
demand.  Understanding the molecular mechanism of this 
complex process gives the opportunity to identify the underlying 
molecular deregulation in haematopoietic malignancies. The 
different levels of deregulation include hyperproliferation, 
block in differentiation and sensitivity to growth factors. In this 
review, leukaemic transformation is selected to give evidence 
of cell signalling deregulation. The clinical implications will be 
reviewed in the context of the potential opportunities in the 
future to identify specific therapeutic patient groups that can be 
defined using prognostic and predictive biomarkers.
* corresponding author
Introduction
The quiescent haematopoietic stem cell (HSC) compartment 
maintains a multipotent cell population and gives rise to 
oligolineage progenitors. These progenitors expand to maintain 
the haematopoietic compartment and differentiate into various 
blood lineage progenitors. Lineage positive progenitors are 
committed for differentiation into mature functional blood 
cells.   
Lineage commitment in haematopoiesis
Transcription factors have a pivotal role in haematopoiesis 
and regulate HSC early development, survival, proliferation and 
lineage commitment. Transcription factors, including Runx1, 
SCL, Gata-2, ALL-1 and Evi-1 maintain a gene expression 
program unique to HSCs.1 The maintenance of HSC self-renewal 
requires specific transcription factors among which are HoxB42, 
Notch1 3 and Bmi-1.4 
Oligolineage progenitors originate from the HSC and 
develop into either the common myeloid precursor (CMP) 
or the common lymphoid precursor (CLP), in the latter case 
through the down regulation of PU.1.5 The CMPs undergo further 
lineage divergence into megakaryocytic/erythroid progenitors 
(MEPs) and granulocytic/monocytic progenitors (GMPs) upon 
Gata-1 and PU.1 mutually exclusive expression, respectively.  C/
EBPs, including C/EBPα and C/EBPε  play an important role 
in the granulocytic branch of myelomonocytic commitment 
both through cell-cycle arrest 6 and the up-regulation of tissue 
specific genes.7 Under the influence of PU.1, GATA-3 and Ikaros 
transcription factors, HSCs give rise to CLPs.8 Upregulation 
of such transcription factors determine the commitment of 
the lymphoid lineage and subsequently the downregulation of 
myeloid lineage transcription factors such as GATA-1, C/EBPα, 
and NFE2.9  
Differentiation of lineage 
committed progenitors
Upon commitment to the lymphoid lineage, lymphocyte 
progenitors start their maturation in the bone marrow and 
differentiate either as mature T cells in the thymus gland 
or as mature B cells in germinal centres (GCs) of secondary 
lymphoid organs. Lymphocyte fate is under tight regulation 
of mutually exclusive transcription factors and signalling 
pathways, which force CLP differentiation into a pro-B cell or 
a pro-T cell. Increased expression levels of E2A, EBF, Bcl11a10 
and PAX511,12 promote CLP differentiation to pro-B cells, pre-B 
cells and further to ‘naive’ B cells by the participation of the 
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SOX413 and LEF114 transcription factors. Consistently, PAX5 
acts as a repressor by recruiting co-repressors to genes encoding 
NOTCH115, therefore direct differentiation towards the B cell 
lineage.  
The microenvironment and the cellular sensitivity to the 
surrounding cytokines and growth factors allows appropriate 
differentiation to various mature cells in response to the 
physiological demand. Upon commitment, progenitors migrate 
to the specific microenvironment and are programmed to express 
lineage specific receptors, as governed by the transcription 
program, altering the sensitivity to the microenvironment. 
Lineage specific cytokines and growth factors regulate 
maintenance and differentiation of the committed progenitor 
cells. For instance, the differentiation towards the T cell lineage 
is promoted via the migration of CLPs to the thymus gland. 
The developmental progression of T cells is initiated by the 
downregulation of genes encoding KIT, CD44 and CD25.16 
This proceeds further to the upregulation of genes encoding 
the NOTCH proteins17,18 and the response to cytokines and 
growth factors, such as IL-7 and morphogens, such as the Sonic 
Hedgehog  proteins.19
Stem Cell Factor (SCF) supports proliferation of various 
haematopoietic compartments. In erythropoeisis the lineage-
specific cytokine erythropoietin (Epo) works in concert with SCF 
to regulate the balance between proliferation and differentiation 
of erythroid progenitors. Epo and SCF transduce signals via 
multiple cooperating pathways in erythroid progenitors.20,21 
Activation of Protein Kinase B (PKB) results in phosphorylation 
of transcription factor Foxo3a, which results in its cytoplasmic 
retention and inhibition of transcriptional activation of cell cycle 
progression inhibitors, such as p27, p130Rb2, Btg1 and cyclin 
G2.22 PKB, also activates the mTOR/eIF4E pathway23 resulting 
in enhanced translation efficiency of structured mRNAs 
representing growth promoting transcripts (Figure 1). Decreased 
SCF signalling results in downregulation of PI3K, releasing 
active Foxo3a that promotes expression of cell cycle inhibitors 
initiating signals that execute terminal differentiation.  
Dysregulation of  haematopoiesis
The balance between proliferation and differentiation of 
committed progenitors is under tight control, to maintain 
the progenitor pool and ensure maturation in response to 
physiological demand. The production of increased numbers 
of mature blood cells during stress, requires higher progenitor 
proliferation rates. Concurrently, feedback mechanisms must 
be closely coordinated to repress progenitor proliferation and 
to restore physiological cell numbers when the stress is over.24 
Deregulation of this balance will result in disease.  
Hyperproliferation 
Myelo-Proliferative Disorders (MPD) and anaemia originate 
from hyperproliferative potential that can be sustained or can 
result in bone marrow exhaustion, respectively.  Constitutive 
active tyrosine kinase receptors (FLT-3, cKit), activated kinases 
like activated Jak2 and mutant phosphatase PTEN promote 
proliferation and/or survival in committed progenitors that are 
still capable of differentiation.  This results in a hyperproliferative 
phenotype.9,25,26 
A common mutational event in lymphoid malignancies is the 
juxtaposition of genes to the BCR or TCR enhancer/promoter 
elements. One classical example is the BCL1 protein or CyclinD1 
in the t(11;14) anomaly, where the BCL1 protein is juxtaposed to 
the Ig gene enhancer. The BCL1 protein is a cell cycle regulator 
required for the cellular maintenance of G1 progression and G1/S 
transition of the cell cycle. The enhancers of the Ig and BCL1 
gene are exchanged leading to the possibility of overexpression 
of BCL1 gene with an accelerated passage through the G1 phase 
of the cell cycle.28 Other similar examples are seen in mature B 
cell malignancies such as the t(14;18) in Follicular lymphomas29, 
the t(1;14) in MALT lymphomas30 and the t(8;14) in Burkiitt 
lymphomas.31 Table 1 summarises the translocations resulting 
in dysregulation of proteins involved in cell cycle regulation and 
apoptosis. Dysregulation is a result of promoter exchange upon 
juxtaposition of one gene to another.
Differentiation block
In addition to hyperproliferation, a perturbed program 
blocking terminal differentiation plays a role in the development 
of leukaemia. Experimental reduction of the terminal 
differentiation transcription factor PU.1, results in leukaemia 
following failed differentiation.5 Translocations t(8:21) and 
t(15;17) give rise to the fusion proteins AML1/RUNX1 and PML-
RARα, both of which inhibit haematopoietic differentiation 
by recruiting repression complexes to target genes of the 
AML1 and RARα transcription factors respectively.32, 33 This 
is also observed in early transformed lymphoid cells where a 
block in differentiation occurs either by the involvement of a 
transcription factor in the generation of a fusion gene or by 
promoter exchange with the BCR or TCR enhancer loci. The 
translocation t(1;19), encoding the E2A-PBX fusion protein, 
blocks the activity of the transcription factor E2A contributing 
to the onset of pre-B ALL.34 In a recurrent chromosomal 
abnormality detected in T-ALL patients, t(1;14), the TAL1 
gene is brought under the influence of the TCRA/D enhancer, 
deregulating the expression of the transcription factor TAL1 
and blocks the T cell differentiation pathway giving rise to the 
onset of T-ALL.35   Table 2 summarises recurrent chromosomal 
translocations found in leukemias that involve transcription 
factors.
Expression of fusion proteins in haematopoietic progenitors 
confers propagation in serial murine transplantation models36,37 
but is not sufficient to induce leukaemia.  Cooperation events 
exemplified by the complementation of Flt3-ITD mutant to 
PML- RARα transgenic bone marrow cells results in 100% 
penetrance of an APL-like disease when transplanted to 
secondary recipients.32 Moreover, chromosomal translocations 
such as the t(9;22)38, t(14;18)39 that are detected in CML and 
NHL respectively, have been also detected in normal and healthy 
individuals without any evidence of malignancy. Supporting 
this evidence is the t(12;21) in monozygotic twins. Studies have 
shown that although both twins may carry the t(12;21) anomaly, 
only the one with the additional mutation, 12p deletion, develops 
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precursor B acute lymphoblastic leukaemia.40 This provides 
strong evidence that a second hit mutation, in addition to any 
other present mutation, is required for leukaemogenesis. It 
is in fact this combination of a proliferative switch together 
with a differentiation-blocking event which usually results in 
hematopoietic malignancy.
Growth factor sensitivity in disease
The high demand of erythrocytes in circulation is satisfied 
by continuous high level of erythroid progenitor expansion and 
differentiation in the bone marrow. Hence, negative feedback 
of EpoR signalling is required to prevent erythrocytosis. EpoR 
mutations resulting in truncations in the C-terminal region lack 
recruitment of the phosphatase SHP-1 resulting in constitutive 
proliferative signals and hypersensitivity to Epo.41 These 
mutants are associated with primary familial polycythemia42 
with normal cell maturation and increased blood cell production. 
Hypersensitivity can be a result of loss of negative feedback but 
also be caused by activating mutations resulting in enhanced 
proliferation and/or survival. For instance the V617F JAK2 
mutation43 is found predominantly in Polycythemia Vera (PV) 
patients, a myeloproliferative disorder (MPD) characterized 
by massive erythrocytosis. The mutation resides in the kinase 
inhibitory domain, resulting in constitutive JAK2 kinase 
activity. Pro-proliferative signal transduction pathway mutants 
have a central role in the pathogenesis of MPD and require 
cooperative events that lead to leukaemia. In human disease, 
constitutive activating mutations in FLT3 are found in 30-35% 
of adult AML, N-RAS and K-RAS mutations in 20% and cKIT 
mutations account for 5% of cases,27,44 supporting the hypothesis 
that tyrosine kinase receptor mutations represent collaborative 
events in leukaemogenesis together with loss or gain of function 
mutations in haematopoietic transcription factors such as 
AML1, GATA-1, C/EBPα and PU1. In addition to mutations 
that deregulate kinases, a number of translocations  involving 
kinase molecules, are summarised in Table 3.  
Table 1: Dysregulation of proteins involved in cell cycle regulation and apoptosis. In these translocations, fusion genes 
are not generated but dysregulation is brought about by promoter exchange upon juxtaposition of one gene to another
Chromosomal Gene Function of Associated References
Translocation involved  deregulated gene  Phenotype/disease
t(14;18)(q32;q21) BCL2 Apoptotic inhibition Follicular lymphoma 29
t(11;14)(q13;q32) BCL1 Overexpression accelerates  Mantle cell lymphoma 28
  passage through the G1 phase  
t(1;14)(q21;q32) BCL9 Apoptosis inhibition through NF-κB Mucosa associated  30
   lymphoid tissue
3q27 rearrangements BCL6 Bind to sequence specific DNA and  Diffuse Large 59
  repress its transcription in addition  B cell Lymphoma
  to recruiting other protein repressors;
  Cell cycle control;
  Apoptosis inhibition  
t(8;14)(q24;q32) c-MYC Constitutive activation of c-myc Burkitt lymphoma 31
Table 2: Transcription factors commonly involved in recurrent chromosomal translocations in leukemias
Chromosomal  Fusion Fusion Protein – Associated References
Translocation gene   oncogenic function phenotype
T(8;21)(q22;q22) AML1-ETO Recruitment of repression complex;  AML - FAB M2 subtype  53
  negative dominance of ETO on AML1 
T(12;21)(p12;q22) TEL-AML1 Recruitment of repression complex;  B-ALL  54
  negative dominance of TEL on AML1
T(15;17)(q22;q21) PML-RARA Dysregulation of retinoid-inducible genes  AML – FAB M3 subtype  55
  involved in myeloid differentiation; 
  Higher binding affinity for HDACs
T(16;21)(p11;q22) TLS-ERG Seems to act as a transcriptional activator de novo acute   56
   myeloid leukemia
T(1;19)(q23;p13) E2A-PBX1 Potent transcriptional activator with  pre B ALL  57
  pleiotropic transforming activity 
T(3;21)(q26;q22) AML1-EVI1 Chimeric transcription factor with the dual  CML-BC of   58
  functions of AML1 and EVI1:  differentiation  myeloid type;
  block (due to Runt) and stimulation  AML and MDS 
  of proliferation (from the zn fingers)
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Figure 1: Stem cell factor (SCF) signalling pathway. SCF binds to the tyrosine kinase receptor, cKit, activating the 
PI3K/PKB signal transduction pathway. PKB phosphorylates and redistributes Fox3a, sequestrating the molecule from 
the nucleus, inhibiting transcription of cell cycle inhibitors. In addition, activation of mTOR results in the translation of 
growth factors (eIF4E sensitive mRNA transcripts) that are otherwise not recruited to polysomes
Conversely, in myelodysplastic syndrome (MDS) lack of 
circulating erythrocytes occurs due to impaired responsiveness 
to Epo45 or aberrant response to inhibitory cytokines. Epo 
stimulation of erythroid progenitors derived from MDS bone 
marrow fail to induce DNA-binding of transcription factor 
Stat5,45 suggesting that dysplastic cells result from maturation 
commitment without the capacity to drive the terminal 
differentiation program.     
Signalling deregulation 
in leukaemia transformation
Mutations that enhance the translation machinery also 
play a central role in enhanced aggressiveness of various 
human cancers including AML.46 The D816V mutation in the 
kinase domain of cKit activates the PI3K/PKB/mTOR pathway 
conferring sensitivity to rapamycin.47 Interestingly, rapamycin 
induces cell cycle arrest and apoptosis in patient-derived 
neoplastic mast cells harbouring the D816V cKIT, but not in 
Table 3: Table showing deregulated kinases involved in chromosomal translocations contributing 
to the onset of leukemia
Chromosomal Protein Fusion Associated Reference
Translocation kinases gene  Phenotype
t(9;22)(q34;q11) ABL  BCR - ABL CML;  ALL;  AML  60
t(9;12)(q34;p13) ABL TEL - ABL CML;  ALL;  AML  61
t(9;12)(p24;p13) JAK2 TEL  - JAK2 T-ALL;   CD10+-ALL;   62
   ‘CML-like’ disease in transformation 
t(9;22)(p24;q11.2) JAK2 BCR-JAK2 Typical CML  63
t(2;5)( p23;q35) ALK NPM-ALK Anaplastic large cell lymphoma  64
t(5;12)(q33;p13) PDGFR TEL-PDGFR CMML  27
t(12;15)(p13;q25) NTRK3  TEL-NTRK3 AML -  FAB M2 subtype  65
     66
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normal human cord-blood derived mast cells.47 The frequency 
of active PI3K is higher than the incidence of mutations in RAS 
or in the receptor tyrosine kinases (RTK) FLT3 and cKIT,48 
suggesting the need for targeting PI3K downstream effectors. 
Phosphatases that attenuate kinase activity are eligible for 
targeting. The phosphatases, PTEN and pp2a attenuate the 
PI3K/mTOR pathway, directly affecting ribosome biosynthesis 
and translation initiation.23,49 The leukaemic potential of BCR/
ABL-expressing cells can be inhibited by pharmacological 
activation of the phosphatase pp2a.50 This suggests a central role 
of deregulated PI3K/mTOR/translation machinery in chronic 
myeloid leukemia (CML).   
Conclusion and Further Directions
The knowledge of the molecular mechanism underlying 
specific groups of patients gives the opportunity to identify 
specific therapeutic targets that can be treated with known, or 
offer the opportunity to develop, specific pharmaceutical agents. 
To achieve this goal, patients are required to be classified into 
therapeutic groups. As mentioned above, activation of the PI3K 
pathway by various molecular aberrations classifies patients into 
a risk group that is sensitive to rapamycin treatment.  Patients 
with cytogenetic abnormalities  inv(16) (p13q22), and t(8;21)
(q22;q22) are classified as core binding factor  (CBF) leukemias 
(Table 2). These patients are represented into both the good and 
poor prognostic groups. Poor prognosis is driven by mutations 
in the cKit  gene.51 The identification of cKit mutations in CBF 
leukaemia cases is today used as a predictive biomarker strategy 
that will allow the use of specific tyrosine kinase inhibitors, 
such as Imatinib, in the treatment of such cases. Specific 
tyrosine kinase inhibitors are also available for Jak2 positive 
myeloproliferative disorders (MPD); and ABL translocations 
(Table 3). Although still being tested in clinical trials, FLT3 
inhibitors are showing promising results in AML patients that 
carry FLT3 mutations (approximately 30% of AML patients).52 
The BCR/ABL product of the translocation t(9;22)(q34;q11) is 
efficiently and directly targeted by the tyrosine kinase inhibitor, 
Imatinib. Molecular studies of the acquired mutations in the 
BCR/ABL molecule give predictive information on resistance to 
therapy.  Knowledge of these mutations has been used to develop 
new therapeutic drugs to minimise the burden of resistance to 
therapy in CML patients. 
Hence, patients will benefit from the identification of 
additional biomarkers that could predict clinical outcome at 
diagnosis. In addition, prognostic markers that can potentially 
serve as targets for novel agents are continuously investigated. 
Taken together, this knowledge will ensure informed therapeutic 
decisions and allow clinicians to use specific targeted 
therapies.  
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